Fact: Atlanta enjoys assets critical to medtech innovation on par with those in hubs like Boston and the Bay Area. In abundance Atlanta has clinicians, hospitals, patients, universities including two medical schools, engineers, entrepreneurs, solutions providers and supporting state and municipal resources. We are also home for the Centers of Disease Control and Prevention. …
Medtech and life science innovation is intensely rigorous. It requires high levels of acumen and proficiency in multiple disciplines. It can also be immensely capital intensive. Tiffany Wilson founded Atlanta’s Global Center for Medical Innovation (GCMI) in 2012 to help medtech innovators de-risk their technologies, increasing their odds of successful commercialization and positive patient…
New medical technologies for pediatric care face difficult hurdles to commercialization, especially industry investment, due to relatively small market size and the quickly shifting nature of pediatric anatomy. In many cases, compassionate or “expanded use” regulatory pathways are needed to make new technologies available for clinical use in pediatric patients. In December, GCMI Research…
T3 Labs, the industry leading preclinical CRO, a wholly owned subsidiary of GCMI has been acquired by Veranex, a multinational preclinical contract research organization and medtech solution provider, effective November 30, 2023. GCMI will remain a non-profit 501(c)(3) organization and an affiliate of the Georgia Institute of Technology. GCMI will continue to provide medtech…
If you’ve been following our funding series for innovators seeking to spin out new medical technologies from higher ed “environments” like Georgia Tech, you’ll have seen: The Top 5 Medtech and Life Science Funding Resources for GT Faculty, Researchers and Investigators – at Phase Zero, THE Place to Start, and Follow-On, for University Sourced…
In part 1 of our 2023 State of Medtech Design and Development Report we discussed sensors, AI and the paradigm shift in regulatory strategy. Here in part 2, we dive into a persistent need for gap analysis, the importance of focusing on the unmet clinical need, the challenges of manufacturing at scale and investigate…
You’re a university-based researcher, investigator, faculty member or perhaps even a student who has snagged your first funding for the earliest stage commercialization, design and development activities for your potential medical technology. You might even have completed the first activities with that funding and scored $100,000 or more in follow-on funding from GRA, SBIR, or…
Innovation in medical technologies is something of a paradox. On one hand, new technologies that drive innovation can manifest at breakneck speed. On the other hand, the pace at which those technologies breed innovations that reach full commercialization and patient impact can be glacial by comparison. What have been the most significant changes with…
GCMI team members continue to distinguish themselves through industry association or other external recognition. Very recently this was the case for our CEO Sherry Farrugia who was named to the inaugural Atlanta Business Chronicle “Power 10: Health Care list.” From the publication: “There is no shortage of exceptional health care professionals in metro Atlanta.…
Innovation in pediatric technologies that address unmet clinical needs lags behind innovation for adult populations in large part due to its relatively small market size and ROI (return on investment) prospects for industry, continuously changing anatomies of children, and limited populations for testing and clinical trials. Activity sequence and process matters a great deal…